InterCure (INCR) Stock Price, News & Analysis

Company Overview

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

Key Stats

• Today's Range: $1.54 to $1.58
• 50-Day Range: $1.17 to $1.80
• 52-Week Range: $1.17 to $3.72
• Volume: 21,856 shs
• Average Volume: 53,675 shs
• Market Capitalization: $71.16 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

InterCure Stock Analysis - MarketRank™

InterCure scored higher than 21% of companies evaluated by MarketBeat, and ranked 867th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for InterCure.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

InterCure has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.09% of the float of InterCure has been sold short.

Short Interest Ratio / Days to Cover

InterCure has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InterCure has recently decreased by 36.29%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

InterCure does not currently pay a dividend.

Dividend Growth

InterCure does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.09% of the float of InterCure has been sold short.

Short Interest Ratio / Days to Cover

InterCure has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InterCure has recently decreased by 36.29%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: N/A

News Sentiment

InterCure has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for InterCure this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, InterCure insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.24% of the stock of InterCure is held by insiders.

Percentage Held by Institutions

Only 8.34% of the stock of InterCure is held by institutions.

INCR Stock Analysis - Frequently Asked Questions

How have INCR shares performed this year?

InterCure's stock was trading at $1.2898 on January 1st, 2024. Since then, INCR stock has increased by 21.7% and is now trading at $1.57.
View the best growth stocks for 2024 here.

How do I buy shares of InterCure?

Shares of INCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of InterCure own?

Based on aggregate information from My MarketBeat watchlists, some other companies that InterCure investors own include NVIDIA (NVDA), Meta Platforms (META), PayPal (PYPL), Advanced Micro Devices (AMD), Tesla (TSLA), Innovative Industrial Properties (IIPR) and AbbVie (ABBV).

Company Calendar

• Today: 12/30/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:INCR
• CUSIP: N/A
• CIK: 1857030
• Web: www.intercure.co
• Phone: 972774605012
• Fax: N/A
• Employees: 350
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.15
• Current Ratio: 1.78
• Quick Ratio: 1.15

Sales & Book Value

• Annual Sales: $96.61 million
• Price / Sales: 0.77
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.72 per share
• Price / Book: 0.60

Miscellaneous

• Outstanding Shares: 45,570,000
• Free Float: 45,464,000
• Market Cap: $74.11 million
• Optionable: Optionable
• Beta: 1.37